Development of Prognostic Signature Based on Pan-cancer Proteomics

Background: Utilizing genomic data to predict cancer prognosis was insufficient. Proteomics can improve our understanding of the etiology and progression of cancer and improve the assessment of cancer prognosis. Based on CPTAC (Clinical Proteomic Tumor Analysis Consortium) which has generated extensive proteomics data of the vast majority of tumors, we can perform a proteomic pan-carcinoma analysis.Methods: The proteomics data and clinical features of cancer patients were collected from CPTAC. We screened 69 differentially expressed proteins with R software. GO and KEGG analysis were performed to clarify the function of these proteins. The DEPs-based prognostic model was identified by least absolute shrinkage and selection operator (LASSO)-Cox regression model. The time-dependent receiver operating characteristics analysis was used to evaluate the ability of the prognostic model to predict overall survival.Results: A total of 69 differentially expressed proteins were screened in five different types of cancers: hepatocellular carcinoma (HCC), lung adenocarcinoma (LUAD), children's brain tumor tissue consortium (CBTTC), clear cell renal cell carcinoma (CCRC) and uterine corpus endometrial carcinoma (UCEC). Furthermore, the differentially expressed proteins were related to cell metabolism, cell proliferation and extracellular matrix. Then 24 DEPs-based classifiers for predicting OS was developed by LASSO-Cox regression model in training cohort, which was validated in validation cohort. Conclusions: In the present study, we identified DEPs-based survival-predictor model to predict most cancers. We are the first group to utilize proteomics to construct a pan-cancer prognosis model, which could accurately and effectively predict the survival rate of most cancers.

[1]  Jean-David Fumet,et al.  Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. , 2020, European journal of cancer.

[2]  S. Varambally,et al.  Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model , 2020, Translational oncology.

[3]  Chin-Lee Wu,et al.  GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate , 2020, Cancer Research.

[4]  Ying Zheng,et al.  IL33 activates CD8+T and NK cells through MyD88 pathway to suppress the lung cancer cell growth in mice , 2020, Biotechnology Letters.

[5]  J. Tabernero,et al.  Enhancing global access to cancer medicines , 2020, CA: a cancer journal for clinicians.

[6]  K. Leithner.  Epigenetic Marks Repressing Gluconeogenesis in Liver and Kidney Cancer. , 2020, Cancer research.

[7]  Hao Zhao,et al.  Lung Cancer Inhibition by Betulinic Acid Nanoparticles via Adenosine 5′-Triphosphate (ATP)-Binding Cassette Transporter G1 Gene Downregulation , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[8]  Lu Zhang,et al.  Comprehensive Review of Web Servers and Bioinformatics Tools for Cancer Prognosis Analysis , 2020, Frontiers in Oncology.

[9]  Yitao Wang,et al.  Identification and characterization of the promoter of cancer-related gene LOXL2. , 2019, Experimental cell research.

[10]  M. Pellegrini,et al.  Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. , 2019, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  G. Karagiannis,et al.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target , 2019, Oncogene.

[12]  Jessica Burns,et al.  Proteomic research in sarcomas – current status and future opportunities , 2019, Seminars in cancer biology.

[13]  H. Rodriguez,et al.  Cancer Proteomics and the Elusive Diagnostic Biomarkers , 2019, Proteomics.

[14]  Jianlin Chen,et al.  PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients , 2019, Cancer Cell International.

[15]  R. Agami,et al.  A fragment-like approach to PYCR1 inhibition. , 2019, Bioorganic & medicinal chemistry letters.

[16]  W. Curran,et al.  Acetylation regulates ribonucleotide reductase activity and cancer cell growth , 2019, Nature Communications.

[17]  Zhang Hy,et al.  Upregulation of lncRNA CALML3-AS1 promotes cell proliferation and metastasis in cervical cancer via activation of the Wnt/β-catenin pathway. , 2019 .

[18]  J. Qiu,et al.  Accumulation of fructose 1,6-bisphosphate protects clear cell renal cell carcinoma from oxidative stress , 2019, Laboratory Investigation.

[19]  Jing Wang,et al.  A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries , 2019, Disease Models & Mechanisms.

[20]  James E. Muller,et al.  Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal* , 2018, Molecular & Cellular Proteomics.

[21]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[22]  B. Vanderhyden,et al.  miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway. , 2018, Cancer research.

[23]  X. Liu,et al.  Genetic variants in the exon region of versican predict survival of patients with resected early-stage hepatitis B virus-associated hepatocellular carcinoma , 2018, Cancer management and research.

[24]  Yongdai Kim,et al.  Logistic LASSO regression for the diagnosis of breast cancer using clinical demographic data and the BI-RADS lexicon for ultrasonography , 2017, Ultrasonography.

[25]  K. Arga,et al.  Differential co-expression analysis reveals a novel prognostic gene module in ovarian cancer , 2017, Scientific Reports.

[26]  R. Longuespée,et al.  OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages , 2017, Clinical Proteomics.

[27]  I. Judson,et al.  Phosphoproteomics in translational research: a sarcoma perspective. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[29]  Terukazu Nakamura,et al.  CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. , 2014, Urologic oncology.

[30]  P. Szlosarek,et al.  Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[31]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[32]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[33]  Xiangdong Wang,et al.  Role of clinical bioinformatics in the development of network-based Biomarkers , 2011, Journal of Clinical Bioinformatics.

[34]  R. Iozzo,et al.  Decorin is a novel antagonistic ligand of the Met receptor , 2009, The Journal of cell biology.

[35]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[36]  I. Bossis,et al.  An immortalized human cell line bearing a PRKAR1A-inactivating mutation: effects of overexpression of the wild-type Allele and other protein kinase A subunits. , 2008, The Journal of clinical endocrinology and metabolism.

[37]  L. Breeden,et al.  Nascent transcription of MCM2-7 is important for nuclear localization of the minichromosome maintenance complex in G1. , 2007, Molecular biology of the cell.

[38]  P. Bornstein,et al.  Thrombospondin 2, a matricellular protein with diverse functions. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[39]  M. Monden,et al.  Expression and Prognostic Role of Cyclin-Dependent Kinase 1 (cdc2) in Hepatocellular Carcinoma , 2000, Oncology.